小世界衍生指数用于区分阿尔茨海默氏症类型痴呆症和健康受试者
Fabrizio Vecchio1,2, Francesca Miraglia1,2, Chiara Pappalettera1,2
1Brain Connectivity Laboratory, Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele Roma, 00166 Rome, Italy.
Age and ageing
|June 27, 2024
概括
一个新的小世界 (SW) 连接指数,SWcomb,有效地将阿尔茨海默病 (AD) 患者与健康人区分开来. 这种非侵入性EEG生物标志物在阿兹海默症患者中显示出较高的SWcomb值,有助于早期检测.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
- 医学诊断 医学诊断 医学诊断
背景情况:
- 阿尔茨海默病 (AD) 诊断依赖于神经心理模式.
- 目前的诊断方法可能缺乏特异性或侵入性.
- 确定AD可靠的生物标志物对于早期干预至关重要.
研究的目的:
- 引入一种新型的脑电图 (EEG) 指数,SWcomb,用于检测阿尔茨海默病中大脑连接性改变.
- 开发一个统一的指标,整合多个小世界 (SW) 参数.
- 评估SWcomb在区分AD患者与健康对照中的有效性.
主要方法:
- 利用了370名参与者的EEG记录 (200名轻度AD,170名健康).
- 在不同临床中心和设备之间协调获取设置.
- 计算了一个新的小世界 (SW) 连接指数,SWcomb,跨标准EEG频段.
主要成果:
- 健康个体表现出最低的SWcomb值.
- 患有阿尔茨海默氏症的个体表现出明显更高的SWcomb值.
- 该SWcomb指数显示了两组之间的明显区别.
结论:
- 该SWcomb指数作为潜在的阿尔茨海默病的非侵入性生物标志物.
- 这种指数易于执行,成本低廉,并且广泛可访问.
- SWcomb提供了一个有前途的工具来区分AD患者和健康个体.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
相关概念视频
Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
